Kevin Dunleavy is a Staff Writer at Herald-Mail Media. He covers a diverse range of themes including medicine and healthcare, finance, and legal affairs, with a particular focus on topics such as oncology, mental health care, and corporate finance. Kevin's work has been featured in notable publications including Yahoo Sports, Biotech, and Deadspin.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Kevin Dunleavy's coverage revolves around the healthcare and pharmaceutical industry, focusing on regulatory approvals, drug development, M&A activities, and legal settlements. His articles often cite data and press releases to support the information presented.
Given his focus on regulatory approvals and drug developments, Kevin may be interested in receiving pitches related to new drugs or treatments entering clinical trials or seeking FDA approval. Additionally, he might be interested in insights from experts who can provide analysis of pharmaceutical market trends supported by relevant data.
As Kevin's geographic focus is not specified but given the international nature of pharmaceutical companies' operations and regulations, sources with a global perspective on healthcare and pharmaceuticals are likely to resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
For the first time, SK Biopharmaceuticals has struck a settlement with a generics manufacturer who has applied for FDA approval of a copycat version
By: Kevin Dunleavy
Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy pill, Novo Nordisk is testing the GLP-1 in smaller doses in the late-stage
By: Kevin Dunleavy
Aurinia Pharmaceuticals has struck a patent infringement settlement with Teva Pharmaceuticals, which should help stave off Teva's proposed generic to its lupus drug Lupkynis (voclosporin) in the Un
By: Kevin Dunleavy
Eight months after more than doubling down on its construction of a $2 billion drug manufacturing facility in Holly Springs, North Carolina, Roche is making a similar move on the other side of the United States.
By: Kevin Dunleavy
Health and Human Services Secretary Robert F. Kennedy Jr. has joined President Donald Trump in a renewed effort to challenge how the United States formulates its childhood vaccine recommendations.
By: Kevin Dunleavy
Courts in Maryland and Washington, D.C., have rejected lawsuits by two pharma giants against the Centers for Medicare & Medicaid Services' (CMS) drug price negotiation program, introduced by former President Joe Biden under the Inflation Reduction Act (IRA).
Just 16 months after Johnson & Johnson scored its initial FDA approval for Imaavy, the pharma giant has tacked on a label expansion for the monoclonal antibody and potential blockbuster.
By: Kevin Dunleavy
Bausch + Lomb has come up short in a phase 2 trial, testing its combination of dry eye disease drugs Xiidra and Miebo. While the study missed its primary endpoint, the Ontario eye care specialist has seen enough promise in the combo to advance it to phase 3 development, it said on Tuesday.
By: Kevin Dunleavy
Less than a month after initiating a drug recall after cardboard was found in an IV infusion bag, Baxter has initiated voluntary recalls of two other products because of particulate matter.
By: Kevin Dunleavy
The Trump administration looks set to unveil a new slate of most favored nation (MFN) drug pricing deals with several mid-sized biopharma companies, according to Bloomberg.
